Jubilant Generics Limited

Jubilant Life Sciences Limited

Dharam Vir

Sujay Biswas

Mukesh Masand

Vikas Bansal

Rajendra Shekhawat

Mokkapati Umamaheshwar Prasad

Anjul Kumar

Shailendr Dubey

Alka Srivastava Choudhary

Rajesh Kumar

Indranil Nandi

Ashutosh Agarwal

Amit Srivastava

Vaibhav Mishra

Shailendra Kumar Dubey

Ashish Kumar Gupta

Brijesh Kumar Shukla

M Umamaheshwar Prasad

Rohit Chakravarty

Nirmal Kumar

Khushwant Singh

Ratnakar Tripathi

Jai Prakash Verma

Lalit Kumar

Rakesh Tiwari

Shishupal Singh

Deepak Bansal

Bidyut Biswas

Himanchal Mishra

Sankareswaran Srimurugan

Atulya Kumar Panda

Sanjeev Kumar

Kumber Singh

Danish Jamshad

Shailendr Kumar Dubey

Rajendra Singh Shekhawat

Amit Kumar Srivastava

The invention relates to a commercially viable, cost effective and energy efficient process for the preparation of 2-(1H-Imidazol-4-yl)ethanamine or pharmaceutically acceptable salts thereof in high purity and yield via application of continuous flow technology.

Continuous process for the preparation of 2-(1H-imidazol-4-yl) ethanamine and pharmaceutically acceptable salts thereof

The present invention relates to an improved process for the preparation of tetrofosmin or acid addition salt thereof. The present invention also relates to the process for the preparation of tetrofosmin disulfosalicylate salt. Further the present invention also provides the polymorphic form J of disulfosalicylate salt of tetrofosmin.

Process for the preparation of tetrofosmin or acid salt thereof

Disclosed herein is an improved process for the preparation of Lurasidone and its pharmaceutically acceptable salts via novel intermediate and use thereof for the preparation of an antipsychotic agent useful for the treatment of schizophrenia and bipolar disorder. Further, present invention provides a cost effective and eco-friendly process for producing Lurasidone hydrochloride of formula (I) substantially free of residual solvent(s) at industrial scale.

Process for the preparation of Lurasidone hydrochloride

The present invention provides an improved process for the preparation of exametazime, which is used as ligand in preparation of technetium-99m complex. 

Process for the preparation of exametazime

The present invention relates to an improved process for the preparation of Apixaban and intermediates thereof. Further the present invention also relates to novel intermediate of Formula V and its process for the preparation.

Process for the preparation of apixaban and intermediates thereof

The present invention provides a novel process for the preparation of substituted optically pure (S)-(+)- or (R)-(&#x2212;)-10-hydroxy-dihydrodibenz[b,f]azepines or derivatives thereof, starting from 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepines using boronate esters or their derivatives. The present invention also provides use of thus prepared (S)-(+)- or (R)-(&#x2212;)-10-hydroxy-dihydrodibenz[b,f]azepines for the preparation of their ester such as (S)-(&#x2212;)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide or (R)-(+)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. The present invention also provides novel solid state crystalline forms J, J, J, Jand amorphous form of eslicarbazepine and the process for the preparation thereof. Also, the present invention provides novel solid state crystalline form and amorphous form of eslicarbazepine acetate and the process for the preparation thereof. The novel solid state forms of eslicarbazepine are useful for the preparation of derivatives of eslicarbazepine such as eslicarbazepine acetate.

Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof

The present invention relates to an improved process for the preparation of azilsartan or its esters or salts thereof. Specifically, the invention provides a method for the preparation of highly pure methyl 1-[[2'-(4,5-dihydro-5-oxo-4H-1,2,4-oxa-diazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate an intermediate compound of formula (4) for azilsartan medoxomil with reduced content of desethyl impurity. The invention also involves the use of highly pure methyl 1-[[2&#x2032;-(4,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate in the preparation of azilsartan or its esters or salts thereof, preferably medoxomil with reduced content of desethyl impurity.

Process for the preparation of azilsartan medoxomil

The present invention provides a novel process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren, or a salt thereof, preferably Aliskiren hemifumarate.

Process for the preparation of aliskiren

Growing community of inventors

Uttar Pradesh, India

Dharam Vir